On 15 October 2026, Amazon.com (NasdaqGS:AMZN) received an FDA warning letter over unapproved drug products for sexually transmitted infections. The FDA cited multiple marketplace listings that it says were marketed as treatments or cures without required drug approvals. Regulators warned that continued sale of these items could trigger product seizures or injunctions if Amazon does not correct the issues. The FDA warning over unapproved STI treatments is important, but should sit alongside everything else you know about Amazon. Take a look at 5 other big wins we have identified for Amazon.com. Consider widening your watchlist to other companies linked to digital infrastructure and cloud demand via 55 AI infrastructure stocks.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.